pre-update Archives

ブログ

How has the Inflation Reduction Act Impacted the Biosimilars Market?

The Inflation Reduction Act (IRA), one of the key legislative achievements the Biden-Harris administration, aims…

Certara2024年8月27日

Fact Sheet

Phoenix™ NLME

Certara2024年8月26日

Fact Sheet

Phoenix™ PK/PD Platform Overview

Certara2024年8月26日

Press Coverage

FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

Certara2024年8月26日

Publication

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…

Certara2024年8月26日

Publication

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…

Certara2024年8月26日

Press Coverage

The Uncertain Path Forward for Psychedelic Medicine

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

Certara2024年8月26日

Blog

Streamline your clinical trials with automated metadata management

When it comes to efficient clinical study build, content is king. Most importantly: metadata content.…

Certara2024年8月26日

Blog

Regulatory requirements for annotated CRFs made easy

aCRFs are a mandatory requirement of the FDA, and therefore a key submission deliverable for…

Certara2024年8月26日

Blog

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…

Certara2024年8月23日

pre-update

How has the Inflation Reduction Act Impacted the Biosimilars Market?

Phoenix™ NLME

Phoenix™ PK/PD Platform Overview

FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The Uncertain Path Forward for Psychedelic Medicine

Streamline your clinical trials with automated metadata management

Regulatory requirements for annotated CRFs made easy

Resmetirom: A pioneering NASH clinical program

メルマガ登録

クイックアクセス

ソリューション

お問合せ